KemPharm to Present at the Benzinga Healthcare Small Cap Conference
September 27 2021 - 7:30AM
KemPharm, Inc. (NASDAQ: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, today announced that Travis C. Mickle, Ph.D.,
President and Chief Executive Officer of KemPharm, will present at
the Benzinga Healthcare Small Cap Conference taking place September
29-30, 2001. The presentation will be available on the conference’s
virtual platform to all registered attendees.
Details of the presentation are as follows:
Event: |
Benzinga Healthcare Small Cap Conference |
Date: |
September 30, 2021 |
Time: |
4:20 p.m., ET |
Registration: |
https://www.benzinga.com/events/small-cap/healthcare/ |
Following the conclusion of the event, a
recording of Dr. Mickle’s presentation will be available under
“Events & Presentations” in the Investor Relations section of
the Company’s website at http://www.kempharm.com.
About KemPharm:KemPharm is a
specialty pharmaceutical company focused on the discovery and
development of proprietary prodrugs to treat serious medical
conditions through its proprietary LAT® (Ligand Activated Therapy)
technology. KemPharm utilizes its proprietary LAT® technology to
generate improved prodrug versions of FDA-approved drugs as well as
to generate prodrug versions of existing compounds that may have
applications for new disease indications. KemPharm’s prodrug
product candidate pipeline is focused on the high need areas of
attention deficit hyperactivity disorder, or ADHD, stimulant use
disorder (SUD) and CNS rare diseases, including idiopathic
hypersomnia (IH). KemPharm’s lead clinical development candidate
for the treatment of SUD, KP879, is based on its prodrug of
d-methylphenidate, known as serdexmethylphenidate (SDX). In
addition, KemPharm has received FDA approval for AZSTARYS™, a new
once-daily treatment for ADHD in patents age six years and older,
and for APADAZ®, an immediate-release combination product
containing benzhydrocodone, a prodrug of hydrocodone, and
acetaminophen. For more information on KemPharm and its pipeline of
prodrug product candidates visit www.kempharm.com or connect with
us on Twitter, LinkedIn, Facebook and YouTube.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Aug 2024 to Sep 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Sep 2023 to Sep 2024